cretostimogene grenadenorepvec
AXP000006.2 · Oncolytic virus
- Platform
- adenovirus (Ad5, E2F-1 promoter-driven E1A, E3-deleted)
- Originator
- Cell Genesys
- Sponsor
- CG Oncology
Names
| Name | Type | Source |
|---|---|---|
| cretostimogene grenadenorepvec | preferred name, INN | curator, ncit |
| cretostimogene | INN | ctgov |
| CG0070 | code | ncit |
| Oncolytic Adenovirus Encoding GM-CSF ambiguous | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (CG0070)
- Replication
- conditionally replicating
- Modifications
- E2F-1 promoter drives E1A; E3 region deleted
- Transgenes
- CSF2
- Route
- intravesical
- Source
- evidence
Cross-references
- NCI Thesaurus
- C48412
- FDA UNII
- THP9ML4NTZ
Approvals
No regulatory approval recorded.
Clinical trials (12)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07283835 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Recruiting | Phase 2 | 2025-12-04 | 2027-12-31 | 16 | High-grade Ta/ T1 Papillary Disease Bladder Cancer; Non Muscle Invasive Bladder Cancer |
| NCT06567743 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Recruiting | Phase 2 | 2024-09-16 | 2027-03-31 | 325 | High-Risk Non-Muscle-Invasive Bladder Cancer |
| NCT06253845 | Study of CG0070 After Transurethral Resection in Patients With IR NMIBC | Active not recruiting | Phase 1 | 2024-03-01 | 2027-09 | 20 | Non-muscle Invasive Bladder Cancer |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Active not recruiting | Phase 3 | 2023-12-14 | 2026-11 | 367 | Bladder Cancer; Non Muscle Invasive Bladder Cancer; Urologic Cancer; Urothelial Carcinoma |
| NCT04387461 | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | Completed | Phase 2 | 2020-12-08 | 2023-03-07 | 35 | Non Muscle Invasive Bladder Cancer |
| NCT04452591 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Active not recruiting | Phase 3 | 2020-10-27 | 2030-06-16 | 190 | High-grade Ta/ T1 Papillary Disease Bladder Cancer; Non Muscle Invasive Bladder Cancer |
| NCT04610671 | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | Completed | Phase 1 | 2020-10-26 | 2024-07-25 | 21 | Bladder Cancer; Muscle-Invasive Bladder Carcinoma |
| NCT02365818 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure | Completed | Phase 2 | 2015-06-02 | 2018-08 | 66 | Bladder Cancer |
| NCT02143804 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | Withdrawn | Phase 2 | 2014-03 | 2015-03 | 0 | Bladder Cancer; High Grade; Non Muscle Invasive |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer | Terminated | Phase 2/3 | 2014-03 | 2016-06 | 22 | Bladder Cancer; Carcinoma in Situ; Carcinoma in Situ Concurrent With Papillary Tumors; Transitional Cell Carcinoma |
| NCT00109655 | Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure | Unknown | Phase 1 | 2005-04 | 2008-10 | 75 | Bladder Neoplasms; Carcinoma, Transitional Cell |
| NCT06443944 | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG | Available | Bladder Cancer; Non-Muscle Invasive Bladder Cancer; Urologic Cancer; Urothelial Carcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42508433 | Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. | The Lancet. Oncology | 2026 | cited by trial NCT04452591 |
| PMID 39521884 | Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. | Nature medicine | 2025 | cited by trial NCT04610671 |
| PMID 38844794 | Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. | Nature medicine | 2024 | cited by trial NCT04387461 |
| PMID 28755959 | An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Urologic oncology | 2018 | name in title: CG0070 |
| PMID 23088985 | A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. | The Journal of urology | 2012 | name in title: CG0070 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41325798 | Oncolytic virotherapy: Molecular mechanisms, delivery strategies, and translational insights. | Critical reviews in oncology/hematology | 2026 | name in abstract: CG0070 |
| PMID 41422765 | Urothelial Carcinoma In Situ: Advances in Diagnosis and Management. | Clinical genitourinary cancer | 2026 | name in abstract: CG0070 |
| PMID 41555169 | [Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: cretostimogene grenadenorepvec |
| PMID 41647170 | Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics. | Molecular therapy. Oncology | 2026 | name in abstract: cretostimogene grenadenorepvec |
| PMID 41825577 | Advances in intravesical therapy for non-muscle-invasive bladder cancer. | Critical reviews in oncology/hematology | 2026 | name in abstract: CG0070 |
| PMID 42216552 | Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer. | Frontiers in bioscience (Landmark edition) | 2026 | name in abstract: cretostimogene grenadenorepvec |
| PMID 42260513 | Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances. | BMC urology | 2026 | name in abstract: cretostimogene grenadenorepvec |
| PMID 42362299 | Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer. | The Urologic clinics of North America | 2026 | name in abstract: cretostimogene |
| PMID 42508430 | Cretostimogene grenadenorepvec: promise beyond response. | The Lancet. Oncology | 2026 | name in title: cretostimogene grenadenorepvec |
| PMID 42798234 | Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials. | BJU international | 2026 | name in abstract: cretostimogene grenadenorepvec |
| PMID 42967132 | Bladder-Sparing Therapies for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ: An Upper and a Lower Response Group With an Unstable Boundary. | Cureus | 2026 | name in abstract: cretostimogene |
| PMID 39779686 | Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. | Expert opinion on biological therapy | 2025 | name in abstract: cretostimogene grenadenorepvec |
| PMID 39933135 | New Treatment Options for Non-Muscle-Invasive Bladder Cancer. | American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting | 2025 | name in abstract: CG0070 |
| PMID 40304944 | Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer. | Current oncology reports | 2025 | name in abstract: cretostimogene grenadenorepvec |
| PMID 40584211 | Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer. | Bladder cancer (Amsterdam, Netherlands) | 2025 | name in abstract: CG0070 |
| PMID 40923119 | Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and future directions. | Current opinion in urology | 2025 | name in abstract: cretostimogene grenadenorepvec |
| PMID 40932192 | [INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS]. | Harefuah | 2025 | name in abstract: cretostimogene grenadenorepvec |
| PMID 40948378 | Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer. | Cancer medicine | 2025 | name in abstract: CG0070 |
| PMID 40970394 | Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation. | Current opinion in urology | 2025 | name in abstract: cretostimogene |
| PMID 41300998 | Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions. | Cancers | 2025 | name in abstract: cretostimogene grenadenorepvec |
| PMID 41425090 | Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies. | Frontiers in cell and developmental biology | 2025 | name in abstract: CG0070 |
| PMID 38886756 | Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment. | Journal of experimental & clinical cancer research : CR | 2024 | name in abstract: cretostimogene grenadenorepvec |
| PMID 36949824 | A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy. | SAGE open medicine | 2023 | name in abstract: CG0070 |
| PMID 37410243 | Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer. | Methods in molecular biology (Clifton, N.J.) | 2023 | name in title: CG0070 |
| PMID 35158964 | From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). | Cancers | 2022 | name in abstract: CG0070 |
| PMID 36051251 | Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments. | Archives of pharmacology and therapeutics | 2022 | name in abstract: CG0070 |
| PMID 30462296 | Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. | Japanese journal of clinical oncology | 2019 | name in abstract: CG0070 |
| PMID 27486853 | Oncolytic virus therapy: A new era of cancer treatment at dawn. | Cancer science | 2016 | name in abstract: CG0070 |
| PMID 20629483 | Use of a bioamplification assay to detect nonselective recombinants and assess the genetic stability of oncolytic adenoviruses. | Human gene therapy | 2010 | name in abstract: CG0070 |
| PMID 16397056 | CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2006 | name in title: CG0070 |
| PMID 17003851 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2006 | name in abstract: CG0070 |
Notes
Cell Genesys -> BioSante (2009 merger) -> Cold Genesys (acquired asset 2010); Cold Genesys renamed CG Oncology in March 2020. Kissei holds Japan/Asia rights (2020). Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
cretostimogene grenadenorepvec (AXP000006.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000006.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.